San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, RayzeBio is raising $108,530,514.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Ken Song played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About RayzeBio
RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative robust pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225.Numerous tumor targets have been clinically validated but have yet to be pursued as radiopharmaceuticals. A systematic evaluation was conducted by RayzeBio to identify biologically-relevant, tumor-specific targets suitable for targeted radiotherapy. These targets have high expression on solid tumors with little to no expression on normal tissues.

To learn more about RayzeBio, visit http://rayzebio.com/

Contact:
Ken Song, Chief Executive Officer
415-412-5509
ksong@rayzebio.com
https://www.linkedin.com/in/kssong/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved